참고문헌 (165)

1. South Med J Acosta 92 421 1999 10.1097/00007611-199904000-00015 Zidovudine-associated type B lactic acidosis and hepatic steatosis in an HIV-infected patient 

   상세보기

2. 1999 Agenerase (amprenavir) product monograph [package insert] 

3. Md Med J Aggarwal 45 929 1996 Type B lactic acidosis in an AIDS patient treated with zidovudine 

4. AIDS Altice 13 957 1999 10.1097/00002030-199905280-00012 Nevirapine induced opiate withdrawal among injection drug users with HIV receiving methadone 

   상세보기

5. Med Lett Anonymous 40 117 1998 Choice of lipid-lowering drugs 

6. Antiviral Ther Anonymous 4 suppl 2 75 1999 Reaching a consensus: Lipodystrophy case definition 

7. Med Lett Anonymous 40 55 1998 Repaglinide for type 2 diabetes mellitus 

8. Med Lett Anonymous 41 71 1999 Rosiglitazone for type 2 diabetes mellitus 

9. Antiviral Ther Aproco Study Group on Metabolic Complications 4 suppl 2 45 1999 

10. Am J Gastroenterol Argiris 94 1248 1999 10.1111/j.1572-0241.1999.01074.x Abnormalities of serum amylase and lipase in HIV-positive patients 

    상세보기

11. AIDS Arribas 12 1722 1998 Acute hepatitis in HIV-infected patients during ritonavir therapy 

12. Journal of Acquired Immune Deficiency Syndromes (JAIDS) Bach 14 296 1997 10.1097/00042560-199703010-00017 Indinavir nephrolithiasis in warm climates [letter] 

    상세보기

13. Ann Intern Med Baram 119 345 1993 10.7326/0003-4819-119-4-199308150-00024 Lactic acidosis and AIDS [letter] 

    상세보기

14. Baril L, Idhammou A, Beucler I, et al: Are the decreased lipolytic enzyme activities responsible for the hypertriglyceridemia in PI-treated patients? [abstract 664]. In Program and Abstracts of the 6th Conference on Retroviruses and Opportunistic Infections, Chicago, 1999, p 192 

15. Bartlett 1999 Medical Management of HIV Infection 

16. AIDS Behrens 13 F63 1999 10.1097/00002030-199907090-00001 Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors 

    상세보기

17. Behrens G, Dejam A, Schmidt HHJ, et al: Lipid evaluation and glucose metabolism in HIV-1 positive patients treated with protease inhibitors [abstract 647]. In Program and Abstracts of the 6th Conference on Retroviruses and Opportunistic Infections, Chicago, 1999, p 189 

18. Bernasconi E, Carota A, Magenta L, et al: Metabolic changes in HIV-infected patients treated with protease inhibitors [abstract 178*/12375]. In Program and Abstracts of the 12th World AIDS Conference, Geneva, 1998, p 88 

19. Am J Kidney Dis Berns 30 558 1997 10.1016/S0272-6386(97)90316-4 Acute renal failure due to indinavir crystalluria and nephrolithiasis: Report of two cases 

    상세보기

20. J Intern Med Bissuel 235 367 1994 10.1111/j.1365-2796.1994.tb01088.x Fulminant hepatitis with severe lactate acidosis in HIV-infected patients on didanosine therapy 

    상세보기

21. Boix V, Reus S, Priego M, et al: Expanding the spectrum of protease-induced lipodystrophy [abstract 12398]. In Program and Abstracts of the 12th World AIDS Conference, Geneva, 1998, p 93 

22. Bose T, Tashima KT, Gormley J, et al: The potential impact of efavirenz on methadone maintenance [abstract P552]. In Program and Abstracts of the 9th European Congress of Clinical Microbiology and Infectious Diseases, Berlin, 1999, p 231 

23. N Engl J Med Bouscarat 338 1776 1998 10.1056/NEJM199806113382417 Paronychia and pyogenic granuloma of the great toes in patients treated with indinavir [letter] 

    상세보기

24. N Engl J Med Bouscarat 341 618 1999 10.1056/NEJM199908193410818 Alopecia associated with indinavir therapy [letter] 

    상세보기

25. 10.1097/00002030-199910220-00030 Bourezane Y, Thalamy B, Viel JF, et al: Ingrown toenails and indinavir: Case-control study demonstrates strong relationship [681]. In Program and Abstracts of the 6th Conference on Retroviruses and Opportunistic Infections, Chicago, 1999, p 196 

    상세보기

26. Boxwell DE, Styrt BA: Lactic acidosis in patients receiving nucleoside reverse transcriptase inhibitors [abstract 1284]. In Abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, 1999, p 496 

27. Lancet Brau 349 924 1997 10.1016/S0140-6736(05)62700-6 Severe hepatitis in three AIDS patients treated with indinavir 

    상세보기

28. Brinkman K, Ter Hofstede H, Veerkamp MJ, et al: Fatal lactic acidosis following HAART containing stavudine, lamivudine, and saquinavir [abstract 60998]. In Program and Abstracts of the 12th World AIDS Conference, Geneva, 1998, p 1182 

29. AIDS Brinkman 12 1735 1998 10.1097/00002030-199814000-00004 Adverse effects of reverse transcriptase inhibitors: Mitochondrial toxicity as common pathway 

    상세보기

30. AIDS Brodie 12 2433 1998 10.1097/00002030-199818000-00012 Variation in incidence of indinavir-associated nephrolithiasis among HIV-positive patients 

    상세보기

31. Caldwell R, Rothstein A, Allmon C, et al: Evaluation of protease inhibitor-associated hyperglycemia in a university-based HIV clinic [abstract 12395]. In Program and Abstracts of the 12th World AIDS Conference, Geneva, 1998, p 92 

32. JAMA Carpenter 280 78 1998 10.1001/jama.280.1.78 Antiretroviral therapy for HIV infection in 1998: Updated recommendations of the International AIDS Society-USA Panel 

    상세보기

33. AIDS Carr 12 F51 1998 10.1097/00002030-199807000-00003 A syndrome of peripheral lipodystrophy, hyperlipidemia and insulin resistance in patients receiving HIV protease inhibitors 

    상세보기

34. Lancet Carr 351 1881 1998 10.1016/S0140-6736(98)03391-1 Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance 

    상세보기

35. Carr A, Samaras K, Thorisdottir A, et al: Diagnosis and prediction of HIV protease inhibitor-induced lipodystrophy and impaired glucose tolerance [abstract 641]. In Program and Abstracts of the 6th Conference on Retroviruses and Opportunistic Infections, Chicago, 1999, p 188 

36. Lancet Carr 535 2093 1999 10.1016/S0140-6736(98)08468-2 Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: A cohort study 

    상세보기

37. Carr A, Thorisdottir A, Samaras K, et al: Reversibility of protease inhibitor lipodystrophy syndrome on stopping PIs or switching to nelfinavir [abstract 668]. In Program and Abstracts of the 6th Conference on Retroviruses and Opportunistic Infections, Chicago, 1999, p 193 

38. Chang E, Deleo, Liu YT, et al: The effects of antiretroviral protease inhibitors on serum lipids and glucose in HIV-infected patients [abstract 12381]. In Program and Abstracts of the 12th World AIDS Conference, Geneva, 1998, p 91 

39. Ann Intern Med Chattha 119 345 1993 10.7326/0003-4819-119-4-199308150-00025 Lactic acidosis and AIDS [letter] 

    상세보기

40. Ann Intern Med Chattha 118 37 1993 10.7326/0003-4819-118-1-199301010-00007 Lactic acidosis complicating the acquired immunodeficiency syndrome 

    상세보기

41. Nephrol Dial Transplant Chodock 14 2484 1999 10.1093/ndt/14.10.2484 Survival of a human immunodeficiency patient with nucleoside-induced lactic acidosis-role of haemodialysis treatment 

    상세보기

42. Coplan P, Nikas A, Saah A, et al: No association observed between indinavir therapy for HIV/AIDS and myocardial infarction in 4 clinical trials with 2,825 subjects [abstract 658]. In Program and Abstracts of the 6th Conference on Retroviruses and Opportunistic Infections, Chicago, 1999, p 191 

43. Cortez KJ, Cotteiro RA, Mileno MD, et al: Non-fatal nucleoside analogue-associated lactic acidosis in three HIV-infected patients [abstract 212]. In Program and Abstracts of the 37th Annual Meeting of the Infectious Diseases Society of America, Philadelphia, 1999, p. 76 

44. 1999 Crixivan (indinavir sulfate) capsules product monograph [package insert] 

45. Am J Med Dassopoulos 107 78 1999 10.1016/S0002-9343(99)00169-2 Acute pancreatitis in human immunodeficiency virus-infected patients: A review 

    상세보기

46. Lancet Daudon 349 1294 1997 10.1016/S0140-6736(05)62506-8 Urinary stones in HIV-1-positive patients treated with indinavir [letter] 

    상세보기

47. Deileman J, Gyssens IC, van der Ende MEM, et al: Urologic complaints in relation to indinavir plasma levels in HIV-infected patients [abstract 12372]. In Program and Abstracts of the 12th World AIDS Conference, Geneva, 1998, p 88 

48. Journal of Acquired Immune Deficiency Syndromes (JAIDS) Dong 21 107 1999 Changes in body habitus and serum lipid abnormalities in HIV-positive women on highly active antiretroviral therapy 

49. Antiviral Ther Dube 4 suppl 2 48 1999 Effect of initiating indinavir therapy on glucose metabolism in HIV-infected patients: Results of minimal model analysis [abstract 028]. 1st International Workshop on Adverse Drug Reactions and Lipodystropy in HIV, San Diego, 1999 

50. Lancet Dube 350 713 1997 10.1016/S0140-6736(05)63513-1 Protease inhibitor-associated hyperglycemia 

    상세보기

51. Duong M, Ptit JM, Piroth L, et al: Lipid evaluation and glucose metabolism in HIV-infected patients before and after initiation of protease inhibitor therapy [abstract 1291]. In Abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, 1999, p 498 

52. Antiviral Ther Engelson 4 suppl 2 48 1999 Effect of recombinant human growth hormone in the treatment of visceral fat accumulation in HIV infection interim analysis [abstract 006]. 1st International Workshop on Adverse Drug Reactions and Lipodystropy in HIV, San Diego, 1999 

53. JAMA Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults 269 3015 1993 10.1001/jama.269.23.3015 Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel II) 

    상세보기

54. FDA Medical Bulletin Food and Drug Administration 27 2 3 1997 Protease inhibitors may increase blood glucose in HIV patients 

    상세보기

55. Am J Gastroenterol Fortgang 90 9 1995 Hepatomegaly and steatosis in HIV-infected patients receiving nucleoside analog antiretroviral therapy 

56. 1997 Fortovase (saquinavir) product monograph [package insert] 

57. Lancet Fouty 352 291 1998 10.1016/S0140-6736(05)60266-8 Riboflavin to treat nucleoside analogue-induced lactic acidosis [letter] 

    상세보기

58. AIDS Freiman 7 379 1993 10.1097/00002030-199303000-00012 Hepatomegaly with severe steatosis in HIV-seropositive patients 

    상세보기

59. Antiviral Ther Galli 4 suppl 2 43 1999 Incidence of fat tissue abnormalities in protease inhibitor-naive patients treated with NRTI combinations [abstract 020]. 1st International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, San Diego, 1999 

60. Antiviral Ther Gatell 4 suppl 2 55 1999 One year effects of switching from HIV-1 PIs to nevirapine on metabolic abnormalities [abstract 040]. 1st International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, San Diego, 1999 

61. Urology Gentle 50 508 1997 10.1016/S0090-4295(97)00401-9 Protease inhibitor-induced urolithiasis 

    상세보기

62. Gerber J, Johnson S: Evaluation of urinary pH and specific gravity in the development of indinavir induced renal stones [abstract 12394]. In Program and Abstracts of the 12th World AIDS Conference, Geneva, 1998, p 92 

63. Gharakhanian S, Salhi Y, Nguyen TH: Frequency of lipodystrophy and factors associated with glucose/lipid abnormalities in a cohort of 650 patients treated by protease inhibitors [abstract 642]. In Program and Abstracts of the 6th Conference on Retroviruses and Opportunistic Infections, Chicago, 1999, p 188 

64. Glesby M, Desai A, Erbelding E, et al: High prevalence of impaired glucose tolerance prior to initiating protease inhibitor therapy [abstract 650]. In Program and Abstracts of the 6th Conference on Retroviruses and Opportunistic Infections, Chicago, 1999, p 190 

65. J Infect Dis Grasela 169 1250 1994 10.1093/infdis/169.6.1250 Analysis of potential risk factors associated with the development of pancreatitis in phase I patients with AIDS or AIDS-related complex receiving didanosine 

    상세보기

66. Am J Med Grunfeld 86 27 1989 10.1016/0002-9343(89)90225-8 Hypertriglyceridemia in the acquired immunodeficiency syndrome 

    상세보기

67. J Clin Endocrinol Metab Grunfeld 74 1045 1992 10.1210/jc.74.5.1045 Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome 

    상세보기

68. J Clin Endocrinol Metab Hadigan 84 6 1932 1999 10.1210/jc.84.6.1932 Fasting hyperinsulinemia and changes in regional body composition in human immunodeficiency virus-infected women 

    

69. Lancet Hengel 350 1596 1997 10.1016/S0140-6736(05)64011-1 Benign symmetric lipomatosis associated with protease inhibitors 

    상세보기

70. Ann Intern Med Henry 117 739 1992 10.7326/0003-4819-117-9-739 Recombinant human erythropoietin in the treatment of anemia associated with human immunodeficiency virus infection and zidovudine therapy: Overview of four clinical trials 

    상세보기

71. Lancet Henry 351 1328 1998 10.1016/S0140-6736(05)79053-X Severe premature coronary artery disease with protease inhibitors 

    상세보기

72. Lancet Henry 352 1031 1998 10.1016/S0140-6736(98)00022-1 Atorvastatin and gemfibrozil for protease-inhibitor-related lipid abnormalities 

    상세보기

73. Hirschhorn L, Stone VE, Boswell SL: Discontinuation of protease inhibitor therapy: Reasons and risk factors [abstract 12443]. In Program and Abstracts of the 12th World AIDS Conference, Geneva, 1998, p 101 

74. Juette A, Salzberger B, Franzen C, et al: Increased morbidity from severe coronary heart disease in HIV patients receiving protease inhibitors [abstract 656]. In Program and Abstracts of the 6th Conference on Retroviruses and Opportunistic Infections, Chicago, 1999, p 191 

75. Justman J, Danoff A, Benning L, et al: Association of diabetes and protease inhibitor use in a large natural history cohort of HIV+ women [abstract 661]. In Program and Abstracts of the 6th Conference on Retroviruses and Opportunistic Infections, Chicago, 1999, p 192 

76. Antiviral Ther Kakuda 4 suppl 2 56 1999 NRTI-induced mitochondrial toxicity as an aetiology for fat redistribution syndrome [abstract 041]. 1st International Workshop on Adverse Drug Reactions and Lipodystropy in HIV, San Diego, 1999 

77. Keruly JC, Chaisson RE, Moore RD: Diabetes and hyperglycemia in patients receiving protease inhibitors [abstract 415]. In Program and Abstracts of the 5th Conference on Retroviruses and Opportunistic Infections, Chicago, 1998, p 157 

78. Klein D, Sidney S, Hurley L, et al: Do protease inhibitors increase the risk for coronary heart disease among HIV positive patients? [abstract 657]. In Program and Abstracts of the 6th Conference on Retroviruses and Opportunistic Infections, Chicago, 1999, p 191 

79. N Engl J Med Knopp 341 498 1999 10.1056/NEJM199908123410707 Drug therapy: Treatment of lipid disorders 

    상세보기

80. J Urol Kohan 159 suppl 177 1998 Indinavir urolithiasis: An emerging cause of renal colic in the HIV patients 

81. Ann Intern Med Kopp 127 119 1997 10.7326/0003-4819-127-2-199707150-00004 Crystalluria and urinary tract abnormalities associated with indinavir 

    상세보기

82. Antiviral Ther Kosmiski 4 suppl 2 64 1999 

83. Ann Intern Med Lai 115 283 1991 10.7326/0003-4819-115-4-283 Fulminant hepatic failure associated with 2′,3′-dideoxyinosine 

    상세보기

84. N Engl J Med Lambert 322 1333 1990 10.1056/NEJM199005103221901 2′,3′-dideoxyinosine in patients with the acquired immunodeficiency syndrome or AIDS-related complex: A phase I trial 

    상세보기

85. AIDS LeBras 8 716 1994 Metabolic, hepatic and muscular changes during zidovudine therapy: A drug-induced mitochondrial disease? 

86. Lee D, Mathews WC: Prevalence and risk factors for hyperglycemia, dyslipidemia, and coronary disease among HIV-infected patients on initial protease inhibitor therapy [abstract 644]. In Program and Abstracts of the 6th Conference on Retroviruses and Opportunistic Infections, Chicago, 1999, p 189 

87. Antiviral Ther Lee 4 suppl 2 58 1999 Effect of fenofibrate on hyperlipidemia in HIV-infected patients [abstract 044]. 1st International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, San Diego, 1999 

88. Lenhard JM, Weiel JE, Paulik MA, et al: HIV protease inhibitors block adipogenesis and increase lipolysis in vitro [abstract 666]. In Program and Abstracts of the 6th Conference on Retroviruses and Opportunistic Infections, Chicago, 1999, p 193 

89. AIDS Lenzo 11 1294 1997 10.1097/00002030-199710001-00003 Hepatic steatosis and lactic acidosis associated with stavudine treatment in an HIV patient: A case report 

    상세보기

90. Antiviral Ther Lichtenstein 4 suppl 2 73 1999 Clinical factors related to the severity of fat redistribution in the HIV Outpatient Study (HOPS) [abstract 071]. 1st International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, San Diego, 1999 

91. Lancet Lo 351 867 1998 10.1016/S0140-6736(97)11443-X “Buffalo hump” in men with HIV-1 infection 

    상세보기

92. Ann Intern Med Loed 117 487 1992 10.7326/0003-4819-117-6-487 Zidovudine: Five years later 

    상세보기

93. Lonergan JT, Behling C, Pfander H, et al: Hyperlactatemia and hepatic abnormalities in ten HIV-infected patients receiving nucleoside analog combination regimens [abstract 348]. In Program and Abstracts of the 37th Annual Meeting of the Infectious Diseases Society of America, Philadelphia, 1999, p 100 

94. Lancet Luzzati 353 901 1999 10.1016/S0140-6736(99)00523-1 Riboflavine and severe lactic acidosis [letter] 

    상세보기

95. AIDS Madge 13 735 1999 10.1097/00002030-199904160-00020 Lipodystrophy in patients naive to HIV protease inhibitors 

    상세보기

96. J Urol Mahoney 159 suppl 176 1998 A new type of urinary calculus: Indinavir 

97. Antiviral Ther Mallal 4 suppl 2 42 1999 

98. Martinez E, Leguizamon M, Del Rio A, et al: Indinavir-related nephrolithiasis is associated with environmental temperature [abstract 12399]. In Program and Abstracts of the 12th World AIDS Conference, Geneva, 1998, p 93 

99. 10.1097/00002030-199905070-00009 Martinez E, Lozano L, Conget I, et al: Reversion of lipodystrophy after switching HIV-1 protease inhibitors to nevirapine [abstract 670]. In Program and Abstracts of the 6th Conference on Retroviruses and Opportunistic Infections, Chicago, 1999, p 194 

    상세보기

100. Maserati R, Mussati G, Scudeller L, et al: Hyperbilirubinemia in patients treated with indinavir [abstract 60808]. In Program and Abstracts of the 12th World AIDS Conference, Geneva, 1998, p 1149 

101. Maulin L, Gerard Y, De La Tribonniere X, et al: Emerging complication of antiretroviral therapy: Symptomatic hyperlactatemia [abstract 1285]. In Abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, 1999, p 496 

102. Am J Gastroenterol Maxson 87 708 1992 Acute pancreatitis as a common complication of 2′,3′-dideoxyinosine therapy in the acquired immunodeficiency syndrome 

     상세보기

103. Antiviral Ther Mercie 4 suppl 2 42 1999 Case report of lipodystrophy observations in patients naive of protease inhibitor treatment, Aquitaine Cohort, 1999 [abstract 018]. 1st International Workshop on Adverse Drug Reactions and Lipodystropy in HIV, San Diego, 1999 

104. Lancet Miller 351 871 1998 10.1016/S0140-6736(97)11518-5 Visceral abdominal-fat accumulation associated with use of indinavir 

     상세보기

105. West J Med Miller 160 447 1994 Neuromuscular complications of human immunodeficiency virus infection and antiretroviral therapy 

     상세보기

106. Arch Intern Med Morello 159 1931 1999 10.1001/archinte.159.16.1931 Randomized double-blind study comparing the efficacy of gabapentin with amitriptyline on diabetic peripheral neuropathy pain 

     상세보기

107. Antiviral Ther Moyle 4 suppl 2 63 1999 Lipid elevations during non-nucleoside RTI (NNRTI) therapy: A cross-sectional analysis [abstract 054]. 1st International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, San Diego, 1999 

108. Moyle GJ, Baldwin C, Dent N, et al: Management of protease inhibitor-associated lipodystrophy by substitution with efavirenz in virologically controlled HIV-infected persons [abstract 2064]. In Abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, 1999, p 526 

109. Antiviral Ther Moyle 4 suppl 2 71 1999 Body fat redistribution in persons on non-PI-containing regimens [abstract 053]. 1st International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, San Diego, 1999 

110. Mulligan K, Tai VW, Algren H, et al: Evidence of unique metabolic effects of protease inhibitors [abstract 414]. In Program and Abstracts of the 5th Conference on Retroviruses and Opportunistic Infections, Chicago, 1998, p 157 

111. Muurahainen N, Falutz J, Pettit RD, et al: HIV-associated adipose redistribution syndrome; overweight patients report less lipodystrophy, more fat accumulation [abstract 1301]. In Abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, 1999, p 502 

112. Am J Hematol Mylonakis 60 164 1999 10.1002/(SICI)1096-8652(199902)60:2<164::AID-AJH16>3.0.CO;2-4 Persistent parvovirus B19 related anemia of seven years' duration in an HIV-infected patient: Complete remission associated with highly active antiretroviral therapy 

     상세보기

113. Nelson MR, Gazzard V, Kooner RS, et al: The loin pain/indinavir syndrome and urolithiasis associated with indinavir therapy [abstract 12388]. In Program and Abstracts of the 12th World AIDS Conference, Geneva, 1998, p 91 

114. 1997 Norvir (ritonavir) product monograph [package insert] 

115. Clin Infect Dis Olana 21 973 1995 10.1093/clinids/21.4.973 Massive hepatic steatosis and lactic acidosis in a patient with AIDS who was receiving zidovudine 

     상세보기

116. Penzak SR, Chuck SK, Stajich GV: Efficacy and safety of HMG-CoA reductase inhibitors (statins) for the treatment of protease inhibitor-related hyperlipidemia: A retrospective analysis [abstract 1297]. In Abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, 1999, p 500 

117. Clin Nephrol Perazella 50 194 1998 Indinavir nephropathy in an AIDS patient with renal insufficiency and pyuria 

     상세보기

118. Circulation Periard 100 700 1999 10.1161/01.CIR.100.7.700 Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors 

     상세보기

119. Lancet Ponce-de-Leon 353 1244 1999 10.1016/S0140-6736(99)01172-1 Liposuction for protease-inhibitor associated lipodystrophy 

     상세보기

120. 1998 Procrit (epoetin alfa) product monograph [package insert] 

121. J Urol Reiter 161 1082 1999 10.1016/S0022-5347(01)61595-7 Frequency of urolithiasis in individuals seropositive for human immunodeficiency virus treated with indinavir is higher than previously assumed 

     상세보기

122. 1998 Retrovir (zidovudine) product monograph [package insert] 

123. Rickerts V, Hanel H, Leder T, et al: Sterile leucocyturia and reversible impairment of renal function in indinavir treated patients [abstract 12379]. In Program and Abstracts of the 12th World AIDS Conference, Geneva, 1998, p 89 

124. Ripamonti D, Chiodera A, Nasta P: Tolerability and toxicity of protease inhibitor-containing regimens in HIV infected patients [abstract 12242]. In Program and Abstracts of the 12th World AIDS Conference, Geneva, 1998, p 60 

125. Romeu J, Sirera G, Rego MJ, et al: Cumulative risk for developing hyperlipidemia in HIV-infected patients treated with protease inhibitors [abstract 1293]. In Abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, 1999, p 499 

126. AIDS Roubenoff 13 1373 1999 10.1097/00002030-199907300-00015 A pilot study of exercise training to reduce trunk fat in adults with HIV-associated fat redistribution 

     상세보기

127. Antiviral Ther Rozenbaum 4 suppl 2 71 1999 Prospective follow-up of a PI substitution for efavirenz in patients with HIV-related lipodystrophy syndrome [abstract 068]. 1st International Workshop on Adverse Drug Reactions and Lipodystropy in HIV, San Diego, 1999 

128. Rubin DS, Izhar T, Quavi A: The “steatosis-lactic acidosis syndrome” in early stage HIV infection treated with HAART [abstract 60611]. In Program and Abstracts of the 12th World AIDS Conference, Geneva, 1998, p 1112 

129. Ruiz L, Bonjoch A, Paredes R, et al: A multi-centre, randomized, open-label, comparative trial of the clinical benefit of switching the protease inhibitor by nevirapine in HAART-experienced patients suffering lipodystrophy [LB14]. In Program and Abstracts of the 6th Conference on Retroviruses and Opportunistic Infections, Chicago, 1999, p 207 

130. Saint-Marc T, Poizot-Martin I, Partisani M, et al: A syndrome of lipodystrophy in patients receiving a stable nucleoside analogue therapy [abstract 653]. In Program and Abstracts of the 6th Conference on Retroviruses and Opportunistic Infections, Chicago, 1999, p 190 

131. 10.1097/00002030-199905280-00023 Saint-Marc T, Touraine JL: Effects of metformin on insulin resistance and central adiposity in patients receiving effective protease inhibitor (PI) therapy [abstract 672]. In Program and Abstracts of the 6th Conference on Retroviruses and Opportunistic Infections, Chicago, 1999, p 194 

     상세보기

132. Sala Rodo M, Pena R, Cervantes M, et al: Hyperglycemia associated with protease inhibitor therapy [abstract 12387]. In Program and Abstracts of the 12th World AIDS Conference, Geneva, 1998, p 91 

133. Sarcletti M, Petter A, Lhotta K, et al: Increased risk of indinavir nephropathy in women [abstract 418]. In Program and Abstracts of the 5th Conference on Retroviruses and Opportunistic Infections, Chicago, 1998, p 158 

134. Intensive Care Med Scalfaro 24 247 1998 10.1007/s001340050558 Severe transient neonatal lactic acidosis during prophylactic zidovudine treatment 

     상세보기

135. Schliefer K, Wasmuth JC, Rockstroh JK, et al: Treatment of PI-induced hyperlipidemia with bezafibrate [abstract 1296]. In Abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, 1999, p 500 

136. J Urol Schwartz 161 1085 1999 10.1016/S0022-5347(01)61596-9 Imaging characteristics of indinavir calculi 

     상세보기

137. JAMA Shlay 280 1590 1998 10.1001/jama.280.18.1590 Acupuncture and amitriptyline for pain due to HIV-related peripheral neuropathy: A randomized trial 

     상세보기

138. Journal of Acquired Immune Deficiency Syndromes (JAIDS) Simpson 9 153 1995 Nucleoside analogue-associated peripheral neuropathy in human immunodeficiency virus infection 

139. Slayter KL, Stephens M, Schlech WF, et al: Validation of a dyslipidemia algorithm in HIV-positive patients [abstract 1294]. In Abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, 1999, p 499 

140. Snatos GA, Finkelstein J, Pettit R: Management of HIV-associated adipose redistribution syndrome in women with low-dose recombinant human growth hormone [abstract 1305]. In Abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, 1999, p 503 

141. Steel H, Hetherington S, Pearce G, et al: Abacavir safety and tolerability: Experience from over 25,000 adults and children [abstract 599]. Presented at the 7th European Conference on Clinical Aspects and Treatment of HIV Infection, Lisbon, 1999 

142. Stevens GJ, Chen M, Grecko R, et al: Preclinical investigations into the mechanism by which HIV protease inhibitors may induce metabolic disorders [abstract 1288]. In Abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, 1999, p 497 

143. Crit Care Med Sundar 25 1425 1997 10.1097/00003246-199708000-00034 Zidovudine-induced fatal lactic acidosis and hepatic failure in patients with acquired immunodeficiency syndrome: Report of two patients and review of the literature 

     상세보기

144. 1998 Sustiva (efavirenz capsules) product monograph [package insert] 

145. N Engl J Med Tashima 336 139 1997 10.1056/NEJM199701093360215 Indinavir nephropathy [letter] 

     상세보기

146. Torres R, Unger K: The effect of recombinant human growth hormone on protease-inhibitor-associated fat maldistribution syndrome [abstract 675]. In Program and Abstracts of the 6th Conference on Retroviruses and Opportunistic Infections, Chicago, 1999, p 194 

147. Tsiodras S, Mantzoros C, Hammer SM, et al: Effects of protease inhibitor use on hyperglycemia and hyperlipidemia: A five year analysis [abstract 643]. In Program and Abstracts of the 6th Conference on Retroviruses and Opportunistic Infections, Chicago, 1999, p 189 

148. Antiviral Ther Viard 4 suppl 2 47 1999 Lipodystrophic syndromes in a cohort of HIV-1-infected patients receiving HAART with a protease inhibitor [abstract 026]. 1st International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, San Diego, 1999 

149. 1999 Videx (didanosine) product monograph [package insert] 

150. AIDS Viraben 12 F37 1998 10.1097/00002030-199806000-00001 Indinavir-associated lipodystrophy 

     상세보기

151. 1997 Viracept (nelfinavir) product monograph [package insert] 

152. 1998 Viramune (nevirapine) product monograph [package insert] 

153. Acta Neurol Scand Walker 92 273 1995 10.1111/j.1600-0404.1995.tb00130.x The therapy of respiratory chain encephalomyopathy: A critical review of the past and current perspective 

     상세보기

154. 10.1097/00002030-199815000-00001 Walli RK, Herfort O, Michl GM, et al: Peripheral insulin resistance leading to impaired glucose tolerance in HIV-1 infected patients treated with protease inhibitors [abstract 41177]. In Program and Abstracts of the 12th World AIDS Conference, Geneva, 1998, p 777 

     상세보기

155. AIDS Walli 12 F167 1998 10.1097/00002030-199815000-00001 Treatment with protease inhibitors associated with peripheral insulin resistance and impaired glucose tolerance in HIV-1-infected patients 

     상세보기

156. Antiviral Ther Walli 4 suppl 2 13 1999 ART-associated insulin resistance: frequency, potential causes and possible therapeutic interventions [abstract 005]. 1st International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, San Diego, 1999 

157. Walli RK, Michl GM, Bogner JR, et al: Effects of PPAR-activator troglitazone on protease inhibitor associated peripheral insulin resistance [abstract 673]. In Program and Abstracts of the 6th Conference on Retroviruses and Opportunistic Infections, Chicago, 1999, p 194 

158. Ward DJ, Delaney KM, Moorman AC, et al: Clinical factors related to lipodytrophy severity in the HIV Outpatient Study (HOPS) [abstract 1299]. In Abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, 1999, p 501 

159. Antiviral Ther Ward 4 suppl 2 39 1999 Description of lipodystrophy in the HIV Outpatient Study (HOPS) [abstract 014]. 1st International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, San Diego, 1999 

160. Lancet Warren 351 567 1998 10.1016/S0140-6736(98)24008-6 Nevirapine-associated Stevens-Johnson syndrome 

     상세보기

161. Lancet Wierzbicki 352 1782 1998 10.1016/S0140-6736(05)79858-5 Lipid lowering therapy in patients with HIV infection 

     상세보기

162. J Urol Witte 159 498 1998 10.1016/S0022-5347(01)63960-0 Anuria and acute renal failure resulting from indinavir sulfate induced nephrolithiasis 

     상세보기

163. Workman C, Whittaker W, Dyer W, et al: Combining ritonavir and indinavir decreases indinavir-associated nephrolithiasis [abstract 677]. In Program and Abstracts of the 6th Conference on Retroviruses and Opportunistic Infections, Chicago, 1999, p 195 

164. J Clin Endocrinol Metab Yonovski 84 1925 1999 10.1210/jc.84.6.1925 Endocrine and metabolic evaluation of human immunodeficiency virus-infected patients with evidence of protease inhibitor-associated lipodystrophy 

     상세보기

165. Youle M: Reasons for discontinuation of protease inhibitor treatment: A clinical survey [abstract 32353]. In Program and Abstracts of the 12th World AIDS Conference, Geneva, 1998, p 592 

활용도 Top5 논문

더보기

해당 논문의 주제분야에서 활용도가 높은 상위 5개 콘텐츠를 보여줍니다.
더보기 버튼을 클릭하시면 더 많은 관련자료를 살펴볼 수 있습니다.